Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Change in Cash: 2013-2025

Historic Change in Cash for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to -$113.6 million.

  • Coherus Oncology's Change in Cash fell 83.94% to -$113.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year decrease of 67.29%. This contributed to the annual value of $22.9 million for FY2024, which is 41.80% down from last year.
  • Latest data reveals that Coherus Oncology reported Change in Cash of -$113.6 million as of Q3 2025, which was down 184.45% from $134.5 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Change in Cash registered a high of $156.9 million during Q1 2024, and its lowest value of -$281.7 million during Q1 2021.
  • For the 3-year period, Coherus Oncology's Change in Cash averaged around $3.6 million, with its median value being $7.4 million (2023).
  • In the last 5 years, Coherus Oncology's Change in Cash crashed by 1,884.52% in 2021 and then soared by 430.96% in 2024.
  • Over the past 5 years, Coherus Oncology's Change in Cash (Quarterly) stood at $56.7 million in 2021, then plummeted by 494.07% to -$223.3 million in 2022, then soared by 110.14% to $22.6 million in 2023, then rose by 25.03% to $28.3 million in 2024, then crashed by 83.94% to -$113.6 million in 2025.
  • Its Change in Cash stands at -$113.6 million for Q3 2025, versus $134.5 million for Q2 2025 and -$43.6 million for Q1 2025.